Cashu
AbbVie’s Atogepant Shows Promise in Phase-3 Migraine Treatment Study Results
4 days ago
Stocks
Health Care
abbv
Abbvie
NYSE: ABBV
-2.67 (-1.17%)
226.04
USD
At close at Dec 05, 21:33 UTC
Overview
Loading chart...
Key Stats
Market Cap
399.38B
Dividend Yield
0.00%
P/E Ratio
167.25
EPS
2.41
Revenue
56.33B
Avg. Volume
4.58M
About
What does ABBV do?
AbbVie is a North Chicago-based biopharmaceutical company that develops and sells medicines across various therapeutic areas, employing 50,000 staff since its IPO in January 2013. Key products include Humira, Botox, and NX-13 for ulcerative colitis.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.